Post-menopausal: high risk for breast cancer
Item
post-menopausal women at high risk for development of breast cancer
boolean
C0232970 (UMLS CUI [1,1])
C4047809 (UMLS CUI [1,2])
Hormone replacement therapy
Item
on a stable dose of hormone replacement therapy
boolean
C0282402 (UMLS CUI [1])
Rpfna: Cytology
Item
have cytomophologic evidence of hyperplasia +/- atypia and ki-67 expression >1.5% in benign breast epithelial cells acquired by rpfna
boolean
C3640066 (UMLS CUI [1,1])
C0010819 (UMLS CUI [1,2])
25-oh vitamin d level
Item
serum level of 25-oh vitamin d of at least 30 ng/ml prior to study entry
boolean
C1255280 (UMLS CUI [1])
Willing to participate
Item
willing to have a repeat rpfna and mammogram at 6 months and 12 months (if participating in the open label portion of the study) following initiation of study drug
boolean
C0600109 (UMLS CUI [1,1])
C2348568 (UMLS CUI [1,2])
Osteoporosis or osteoporotic fracture
Item
prior history of osteoporosis or osteoporotic fracture.
boolean
C0521170 (UMLS CUI [1])
Invasive breast cancer
Item
prior history of invasive breast cancer or other invasive cancer within five years from date of study entry.
boolean
C0853879 (UMLS CUI [1])
Cox-2 specific inhibitors or nsaids
Item
current and chronic use of cox-2 specific inhibitors or nsaids
boolean
C1257954 (UMLS CUI [1])
C0003211 (UMLS CUI [2])
Treatment for rheumatoid arthritis or fibromyalgia
Item
receiving treatment for rheumatoid arthritis or fibromyalgia
boolean
C0087111 (UMLS CUI [1,1])
C0003873 (UMLS CUI [1,2])
C0087111 (UMLS CUI [2,1])
C0016053 (UMLS CUI [2,2])
Migraines or perimenopausal symptoms
Item
current history of poorly controlled migraines or perimenopausal symptoms
boolean
C0149931 (UMLS CUI [1])
C0949062 (UMLS CUI [2])
Investigational agents
Item
currently receiving other investigational agents.
boolean
C1875319 (UMLS CUI [1])
Aromatase inhibitor
Item
receipt of more than 6 months of an aromatase inhibitor (anastrozole, exemestane, letrozole, etc.) at any time in the past.
boolean
C0593802 (UMLS CUI [1])